BackPhathom Pharmaceuticals Overview

Phathom Pharmaceuticals Receivables

Latest receivables for PHAT: $81M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$80.72M
121.99% YoYΔ $44.36M vs prior year quarter

Peer average

Loading

Phathom Pharmaceuticals Receivables History

Loading

Phathom Pharmaceuticals vs. peers: Receivables Comparison

Loading

Phathom Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Phathom Pharmaceuticals (PHAT) FAQ

As of the most recent data (March 2026), PHAT shows a receivables of $81M. That compares with $36M in the prior-year period — up 122.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHAT's receivables is now $81M (was $36M) — a 122.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Phathom Pharmaceuticals is outperforming or lagging.

Tracking PHAT's receivables over time shows whether Phathom Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $81M That compares with $36M in the prior-year period — up 122.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Phathom Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $81M) with ownership activity and broader fundamentals.

Phathom Pharmaceuticals's receivables is $81M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.